The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
 
Cynthia G. Leichman
No Relationships to Disclose
 
Shannon L McDonough
No Relationships to Disclose
 
Stephen R Smalley
No Relationships to Disclose
 
Kevin G. Billingsley
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Merck Serono
Consulting or Advisory Role - Merck Serono
Research Funding - Merck Serono
 
Matthew A. Beldner
No Relationships to Disclose
 
Aram F. Hezel
No Relationships to Disclose
 
Mario R. Velasco
No Relationships to Disclose
 
Katherine A Guthrie
No Relationships to Disclose
 
Charles David Blanke
Travel, Accommodations, Expenses - Novartis
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
Speakers' Bureau - Genomic Health